SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 95, Issue 3, Pages -
Publisher
Wiley
Online
2023-03-09
DOI
10.1002/jmv.28641
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
- (2022) Shuai Xia et al. CELL RESEARCH
- Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity
- (2022) Bo Meng et al. NATURE
- Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
- (2022) Daichi Yamasoba et al. CELL
- Association of frailty, age, and biological sex with SARS-CoV-2 mRNA vaccine-induced immunity in older adults
- (2022) Janna R. Shapiro et al. CLINICAL INFECTIOUS DISEASES
- Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines
- (2022) Xin Zhao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave
- (2022) Guanzhu Lu et al. Emerging Microbes & Infections
- Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
- (2022) Izumi Kimura et al. CELL
- Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
- (2022) Akatsuki Saito et al. Cell Host & Microbe
- Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant
- (2022) Panke Qu et al. Cell Host & Microbe
- Pan‐coronavirus fusion inhibitors to combat COVID‐19 and other emerging coronavirus infectious diseases
- (2022) Qiaoshuai Lan et al. JOURNAL OF MEDICAL VIROLOGY
- A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein
- (2022) Songyi Xue et al. Cell Discovery
- Disease Progression of Hospitalized Elderly Patients with Omicron BA.2 Treated with Molnupiravir
- (2022) Yayun Liu et al. Infectious Diseases and Therapy
- High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron
- (2022) Ulrike Baum et al. BMC INFECTIOUS DISEASES
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
- (2022) Qian Wang et al. CELL
- Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization
- (2022) C Paul Morris et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
- (2022) Emi Takashita et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
- (2021) Dami A. Collier et al. NATURE
- Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
- (2021) Akatsuki Saito et al. NATURE
- SARS-CoV-2 spreads through cell-to-cell transmission
- (2021) Cong Zeng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)
- (2021) Shuai Xia et al. Cell Discovery
- Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
- (2020) Shuai Xia et al. CELL RESEARCH
- A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
- (2020) Rui Shi et al. NATURE
- Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)
- (2020) W. Joost Wiersinga et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
- (2019) Shuai Xia et al. Viruses-Basel
- A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
- (2019) Shuai Xia et al. Science Advances
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search